Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil Liposomes for Prevention of CI-AKI in PCI Patients
NCT05475717Phase 2Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of Alprostadil Liposomes for Injection in contrast-induced acute kidney injury (CI-AKI), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Oct 2022; status: terminated.
02
Drugs
Alprostadil Liposomes for Injection
03
Conditions
contrast-induced acute kidney injury (CI-AKI)
Beyond the preview
Go deeper on NCT05475717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05475717.